QJBIOCH(SH:600796) Zheng Quan Zhi Xing·2025-08-27 22:56Core Viewpoint - Qianjiang Biochemical (600796) reported a mixed performance in its 2025 mid-year financial results, with a decline in total revenue but an increase in net profit, indicating improved profitability metrics despite challenges in revenue generation [1]. Financial Performance Summary - Total revenue for the first half of 2025 was 780 million yuan, a decrease of 9.64% year-on-year [1]. - Net profit attributable to shareholders reached 107 million yuan, reflecting a year-on-year increase of 30.24% [1]. - In Q2 2025, total revenue was 402 million yuan, down 17.8% compared to the same quarter last year [1]. - Q2 net profit attributable to shareholders was approximately 76.6 million yuan, up 43.28% year-on-year [1]. - Gross margin improved to 25.96%, an increase of 11.01% year-on-year, while net margin rose to 12.9%, up 69.58% year-on-year [1]. - Total expenses (selling, administrative, and financial) amounted to 96.25 million yuan, accounting for 12.35% of revenue, a decrease of 5.17% year-on-year [1]. - Earnings per share increased to 0.12 yuan, a rise of 33.33% year-on-year, and operating cash flow per share surged to 0.12 yuan, up 1298.31% year-on-year [1]. Balance Sheet Changes - Cash and cash equivalents decreased by 22.92% to 779 million yuan [1]. - Accounts receivable fell by 13.39% to 935 million yuan [1]. - Interest-bearing liabilities decreased by 10.88% to 2.275 billion yuan [1]. - Significant changes in other financial items included a 100% decrease in notes receivable due to a reduction in commercial acceptance bills [9]. Operational Insights - The company’s return on invested capital (ROIC) was reported at 3.56%, indicating weak capital returns [10]. - The net profit margin for the previous year was 7.09%, suggesting average value addition from products or services [10]. - Historical data shows a median ROIC of 5.08% over the past decade, with two years of losses since the company went public, indicating a fragile business model [10]. - The company’s cash flow situation is concerning, with cash and cash equivalents to current liabilities ratio at 99.55% [10]. - The debt situation is also a point of concern, with interest-bearing debt ratio reaching 28.45% [10].